Streptamer isolated donor lymphocytes classified by the EMEA as non ATMP's

05-May-2010 - Germany

STAGE Cell Therapeutics GmbH announced that EMEA has classified CMV-specific as non ATMP's (Advanced Therapy Medicinal Product). The classification as non ATMP substantially reduces the cost and time to market for Streptamer-isolated cell therapeutics.

The Streptamer' technology enables the complete dissociation of reagents used for antigen-specific staining or isolation of T-cells leaving the isolated T-cells phenotypically and functionally undistinguishable from naturally occurring cells.

“We believe that the decision of the EMEA will strongly support our Streptamer technology as a unique platform for high quality and economic generation of cell therapeutics” said Dr. Lothar Germeroth, COO of STAGE.

Streptamer-isolated cells are currently investigated in several clinical studies for treatment of viral infections. Together with academic partners STAGE is planning to extend the Streptamer-based cell therapies to different cancer indications such as leukemia and melanoma.

“We are actively seeking clinical cooperations with researchers who are interested to rapidly advance their preclinical cell therapy projects into the clinics” stated Dr. Herbert Stadler, CEO of STAGE.

With the close academic cooperations STAGE will be able to demonstrate a variety of successful applications of the Streptamer technology in cell therapy providing attractive new treatment options for currently uncurable diseases.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...